according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
7.1	09/30/2023	28137-00022	Date of first issue: 11/04/2014

SECTION 1. IDENTIFICATION

Product name	:	Ezetimibe / Simvastatin Formulation			
Manufacturer or supplier's details					
Company name of supplier	:	Organon & Co.			
Address	:	30 Hudson Street, 33nd floor			
		Jersey City, New Jersey, U.S.A 07302			
Telephone	:	1-551-430-6000			
Emergency telephone	:	1-215-631-6999			
E-mail address	:	EHSSTEWARD@organon.com			
Recommended use of the chemical and restrictions on use					
Recommended use	:	Pharmaceutical			
Restrictions on use	:	Not applicable			

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR
1910.1200)

Skin irritation :	Category 2	
Skin sensitization :	Category 1	
Specific target organ toxicity : - repeated exposure	Category 1 (Liver, muscle, optic nerve, Eye)	
GHS label elements		
Hazard pictograms :		
Signal Word :	Danger	
Hazard Statements :	If small particles are generated during further processing, han dling or by other means, may form combustible dust concentra- tions in air. H315 Causes skin irritation. H317 May cause an allergic skin reaction. H372 Causes damage to organs (Liver, muscle, optic nerve, Eye) through prolonged or repeated exposure.	
Precautionary Statements :	Prevention: P260 Do not breathe dust. P264 Wash skin thoroughly after handling. P270 Do not eat, drink or smoke when using this product. P272 Contaminated work clothing must not be allowed out of	

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
7.1	09/30/2023	28137-00022	Date of first issue: 11/04/2014
		the workplace.	

P280 Wear protective gloves.

Response:

P302 + P352 IF ON SKIN: Wash with plenty of soap and water. P314 Get medical attention if you feel unwell.

P333 + P313 If skin irritation or rash occurs: Get medical attention.

P362 + P364 Take off contaminated clothing and wash it before reuse.

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

Dust contact with the eyes can lead to mechanical irritation.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture	: Mixture	
Components		
Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 10 - < 20
Ezetimibe	163222-33-1	>= 10 - < 20
Simvastatin	79902-63-9	>= 10 - < 20
Magnesium stearate	557-04-0	>= 1 - < 5
A stual concentration is with he	la oo o trodo ooorot	

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice	:	In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	:	In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	•	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	Causes skin irritation. May cause an allergic skin reaction. Causes damage to organs through prolonged or repeated

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

Version 7.1	Revision Date: 09/30/2023		0S Number: 137-00022	Date of last issue: 04/04/2023 Date of first issue: 11/04/2014
Protection of first-aiders Notes to physician		:	First Aid responde and use the recor when the potentia	the eyes can lead to mechanical irritation. ers should pay attention to self-protection, mended personal protective equipment I for exposure exists (see section 8). cally and supportively.
SECTION	5. FIRE-FIGHTING ME	ASL	JRES	
Suita	ble extinguishing media	:	Water spray Alcohol-resistant Carbon dioxide (C Dry chemical	
Unsu media	itable extinguishing	:	None known.	
	ific hazards during fire	:	concentrations, and potential dust exp	dust; fine dust dispersed in air in sufficient nd in the presence of an ignition source is a losion hazard. oustion products may be a hazard to health.
Haza ucts	rdous combustion prod-	:	Carbon oxides Nitrogen oxides (I Fluorine compour Metal oxides	
Spec ods	ific extinguishing meth-	:	cumstances and t Use water spray t	measures that are appropriate to local cir- he surrounding environment. o cool unopened containers. ged containers from fire area if it is safe to do
	ial protective equipment e-fighters	•	In the event of fire	e, wear self-contained breathing apparatus. ective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- tive equipment and emer- gency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

Version 7.1	Revision Date: 09/30/2023	SDS Number: 28137-00022	Date of last issue: 04/04/2023 Date of first issue: 11/04/2014	
		employed in th determine whi Sections 13 ar	s material, as well as those materials and items the cleanup of releases. You will need to th regulations are applicable. Ind 15 of this SDS provide information regarding r national requirements.	
SECTION	N 7. HANDLING AND ST	ORAGE		
Technical measures		causing an exp Provide adequ	Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.	
Loca	al/Total ventilation		adequate ventilation.	
	ce on safe handling		skin or clothing.	
		Do not breathe Do not swallow Avoid contact Wash skin tho Handle in acco practice, base assessment Minimize dust Keep containe Keep away fro Take precautio Do not eat, dri Take care to p environment.	e dust. w. with eyes. roughly after handling. ordance with good industrial hygiene and safety d on the results of the workplace exposure generation and accumulation. r closed when not in use. m heat and sources of ignition. onary measures against static discharges. nk or smoke when using this product. revent spills, waste and minimize release to the	
Con	ditions for safe storage		ly labeled containers.	
Mate	erials to avoid	: Do not store w Strong oxidizir	ubstances and mixtures	

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

inert or nuisance dust	50 Million particles per cubic foot Value type (Form of exposure): TWA (total dust) Basis: OSHA Z-3
	15 mg/m³ Value type (Form of exposure): TWA (total dust) Basis: OSHA Z-3
	5 mg/m³ Value type (Form of exposure): TWA (respirable fraction) Basis: OSHA Z-3

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

Version 7.1	Revision Date: 09/30/2023	SDS Number: 28137-00022		t issue: 04/04/2023 t issue: 11/04/2014					
	Dust, nuisance dust and par- ticulates		 15 Million particles per cubic foot Value type (Form of exposure): TWA (respirable fraction) Basis: OSHA Z-3 10 mg/m³ Value type (Form of exposure): PEL (Total dust) 						
		5 mg/m³ Value type (Fc	Basis: CAL PEL 5 mg/m ³ Value type (Form of exposure): PEL (respirable dust fraction) Basis: CAL PEL						
Compo	onents	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis				
Cellulo	se	9004-34-6	TWA	10 mg/m ³	ACGIH				
			TWA (Res- pirable)	5 mg/m ³	NIOSH REL				
			TWA (total)	10 mg/m ³	NIOSH REL				
			TWA (total dust)	15 mg/m³	OSHA Z-1				
			TWA (respir- able fraction)	5 mg/m ³	OSHA Z-1				
Ezetim	iibe	163222-33-1	TWA	25 µg/m3 (OEB 3)	Internal				
			Wipe limit	250 µg/100 cm ²	Internal				
Simvas	statin	79902-63-9	TWA	25 µg/m3 (OEB 3)	Internal				
		Further inform	ation: DSEN						
			Wipe limit	250 µg/100 cm ²	Internal				
Magne	esium stearate	557-04-0	TWA (Inhal-	10 mg/m ³	ACGIH				
			able particu-						
			late matter)						
			TWA (Res-	3 mg/m³	ACGIH				
			pirable par-						
			ticulate mat-						
			ter)						

Engineering measures

: All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

Version 7.1	Revision Date: 09/30/2023	SDS Number: 28137-00022	Date of last issue: 04/04/2023 Date of first issue: 11/04/2014
Hand	protection	hazardous ch supplied resp release, expo	ng respirators against exposure to any memical is limited. Use a positive pressure air prator if there is any potential for uncontrolled posure levels are unknown, or any other where air purifying respirators may not provide tection.
Ma	terial	: Chemical-res	istant gloves
	marks rotection	If the work er mists or aero Wear a faces	ble gloving. glasses with side shields or goggles. wironment or activity involves dusty conditions, sols, wear the appropriate goggles. hield or other full face protection if there is a direct contact to the face with dusts, mists, or
Skin a	nd body protection	: Work uniform Additional bo task being pe disposable su	or laboratory coat. dy garments should be used based upon the erformed (e.g., sleevelets, apron, gauntlets, uits) to avoid exposed skin surfaces. ate degowning techniques to remove potentially clothing.
Hygiei	ne measures	: If exposure to eye flushing s working place When using o Contaminate workplace. Wash contam The effective engineering o appropriate o industrial hyg	o chemical is likely during typical use, provide systems and safety showers close to the

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Color	:	No data available
Odor	:	No data available
Odor Threshold	:	No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

Vers 7.1	sion	Revision Date: 09/30/2023		S Number: 37-00022	Date of last issue: 04/04/2023 Date of first issue: 11/04/2014
	Flash p	oint		No data available	х.
	r iaon p	oint	•		·
	Evapor	ation rate	:	No data available	
	Flamma	ability (solid, gas)	:	May form explosi handling or other	ve dust-air mixture during processing, means.
	Flamma	ability (liquids)	:	No data available	
		explosion limit / Upper bility limit	:	No data available	
		explosion limit / Lower bility limit	:	No data available)
	Vapor p	pressure	:	No data available)
	Relative	e vapor density	:	No data available)
	Relative	e density	:	No data available)
	Solubili Wat	ty(ies) er solubility	:	No data available)
	Partition octanol	n coefficient: n-	:	No data available	
		hition temperature	:	No data available	
	Decom	position temperature	:	No data available)
	Viscosi [.] Visc	ty sosity, kinematic	:	No data available	
	Explosi	ve properties	:	Not explosive	
	Uxiaizir	ng properties	÷	i ne substance o	r mixture is not classified as oxidizing.
	Molecu	lar weight	:	No data available	
	Particle	size	:	No data available	

SECTION 10. STABILITY AND REACTIVITY

Reactivity Chemical stability Possibility of hazardous reac- tions	:	Not classified as a reactivity hazard. Stable under normal conditions. May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks.

according to the OSHA Hazard Communication Standard



Version 7.1	Revision Date: 09/30/2023		S Number: 137-00022	Date of last issue: 04/04/2023 Date of first issue: 11/04/2014
Haza	mpatible materials ardous decomposition lucts	:		
SECTION	N 11. TOXICOLOGICAL I	NFC	ORMATION	
Inha Skin Inge	rmation on likely routes lation contact estion contact	of	exposure	
Not	te toxicity classified based on availa	ble	information.	
	nponents:			
	ulose: te oral toxicity	:	LD50 (Rat): :	> 5,000 mg/kg
Acut	te inhalation toxicity	:	LC50 (Rat): : Exposure tim Test atmospl	
Acut	te dermal toxicity	:	LD50 (Rabbi	t): > 2,000 mg/kg
Ezet	timibe:			
Acut	te oral toxicity	:	LD50 (Rat): >	> 5,000 mg/kg
			LD50 (Mouse	e): > 5,000 mg/kg
			LD50 (Dog):	> 3,000 mg/kg
Acut	te inhalation toxicity	:	Remarks: No	data available
Acut	te dermal toxicity	:	Remarks: No	data available
	te toxicity (other routes of inistration)	:		> 2,000 mg/kg Route: Intraperitoneal
				e): > 1,000 - < 2,000 mg/kg toute: Intraperitoneal
Sim	vastatin:			
Acut	te oral toxicity	:	LD50 (Rat): 5	5,000 mg/kg
			LD50 (Mouse	e): 3,800 mg/kg
-	nesium stearate: te oral toxicity	:		> 2,000 mg/kg CD Test Guideline 423

according to the OSHA Hazard Communication Standard



Assessment: The substance or mixture has no acute or al ticity Remarks: Based on data from similar materials Acute dermal toxicity LD50 (Rabbit): > 2,000 mg/kg Remarks: Based on data from similar materials Skin corrosion/irritation Causes skin irritation. Components: Ezetimibe: Species : Result : Species : Remarks : Species : Remarks : Species : Remarks : Species : Result : Result : Result : Species : Result : Species : Species : Species : <th>sion</th> <th>Revision Date: 09/30/2023</th> <th></th> <th>S Number: 137-00022</th> <th>Date of last issue: 04/04/2023 Date of first issue: 11/04/2014</th>	sion	Revision Date: 09/30/2023		S Number: 137-00022	Date of last issue: 04/04/2023 Date of first issue: 11/04/2014
Remarks: Based on data from similar materials Skin corrosion/irritation. Causes skin irritation. Components: Ezetimibe: Species Rabbit Remarks: No skin irritation Sinvastatin: Species Species Rabbit Remarks No skin irritation Sinvastatin: Species Species Rabbit Remarks Moderate skin irritation Species Rabbit Remarks No skin irritation Magnesium stearate: Species Species Rabbit Remarks No skin irritation Remarks Based on data from similar materials Serious eye damage/eye irritation Species Not classified based on available information. Species Components: Species Systems Rabbit Remarks No eye irritation Sinvastatin: Species Species Rabbit Remarks slight irritation Sinvastatin: Species Species Ra				icity	
Causes skin irritation. Components: Ezetimibe: Species Rabbit Result Remarks Rabbit Remarks Rabbit Result Result Result Rabbit Result Result Remarks Rabbit Result Result Result Rabbit Result Result Result Rabbit Result Result Result Rabbit Result Result Result Rabbit R	Acute	dermal toxicity	:		
Components: Ezetimibe: Species : Result : Species : <td></td> <td></td> <td></td> <td></td> <td></td>					
Ezetimibe: Species : Result : No skin irritation Sinvastatin: Species : Species : Remarks : Magnesium stearate: Species : Species : Remarks : Magnesium stearate: Species : Species : Result : Remarks : No skin irritation Result : No skin irritation Remarks : Based on data from similar materials Serious eye damage/eye irritation Not classified based on available information. Components: Ezetimibe: Species : Result : Species Sinvastatin: Species Species Sinvastatin: Species Species Sinvastatin: Species Species Singht irritation Magnesium stearate: Species Species Singht irritation Magnesium stearate: Species Species Result Result Species Result Species Result Result Result Species Species Result Species Result					
Species:Rabbit No skin irritationSinvastatin: Species:Na skin irritationSinvastatin: Remarks:Nabbit Rebit Remarks:Species:Rabbit Result:Species:Rabbit Result:Result:No skin irritation Remarks:Serious eye damage/eye irritation Remarks::Not classified based on available information.:Components: 					
Result : No skin irritation Simvastatin: : Species : Rabbit Remarks : Moderate skin irritation Magnesium stearate: : Species : Rabbit Species : Rabbit Result : No skin irritation Result : No skin irritation Result : No skin irritation Remarks : Based on data from similar materials : Serious eye damage/eye irritation Remarks : Based on data from similar materials : : Serious eye damage/eye irritation : : : : Not classified based on available information. : : : : Species : Rabbit : <td< td=""><td></td><td></td><td></td><td>Rabbit</td><td></td></td<>				Rabbit	
Species:RabbitRemarks:Moderate skin irritationMagnesium stearate::RabbitSpecies:RabbitResult:No skin irritationResult:No skin irritationRemarks:Based on data from similar materialsSerious eye damage/eye irritation.Not classified based on available information.Components:Ezetimibe:Species:Result:No eye irritationSinvastatin:Species:Remarks:Species:Remarks:Species:Result:Species:Result:Species:Result:Species:Result:Species:Result:Species:Result:Species:Result:Species:Result:Species:Result:Species:Result:Species:Result:Result:Result:Result:Result:Result:Result:Result:Result:Result:Result:Result:Result <td></td> <td></td> <td>:</td> <td></td> <td>on</td>			:		on
Remarks : Moderate skin irritation Magnesium stearate: Species Species : Rabbit Result : No skin irritation Remarks : Based on data from similar materials Serious eye damage/eye irritation Not classified based on available information. Components: Ezetimibe: Species : Rabbit Result : No eye irritation Sinvastatin: : Species : Rabbit Remarks : Slight irritation Magnesium stearate: : Species : Rabbit Remarks : Slight irritation Sinvastatin: : Species : Rabbit Remarks : Slight irritation Magnesium stearate: : Species : Rabbit Result : No eye irritation Result : No eye irritation Result : Slaged on data from similar materials Respiratory or skin sensitization : Rabbit Remarks : Based on data from similar materials Respiratory or skin sensitization : Magnesian allergic	Simva	astatin:			
Magnesium stearate: Species : Result : No skin irritation Remarks : Based on data from similar materials Serious eye damage/eye irritation Not classified based on available information. Components: Ezetimibe: Species : Result : Sonvastatin: Species : Remarks : Species : Remarks : Silight irritation Magnesium stearate: Species : Species : Result : Species : Remarks : Silight irritation Magnesium stearate: Species : Result : Species<			:	Rabbit	
Species : Rabbit Result : No skin irritation Remarks : Based on data from similar materials Serious eye damage/eye irritation Not classified based on available information. Components: Ezetimibe: . Species : Result : No eye irritation Sinvastatin: Species : Result : No eye irritation Species : Rabbit Result : No eye irritation Species : Rabbit Result : Species : Result : Species : Remarks : Species : Result : No eye irritation Result : Result : Result : Result : Result : Based on data from similar materials Result : Result : Mag cause an allergic skin reaction.	Rema	irks	:	Moderate skin	irritation
Result:No skin irritationRemarks:Based on data from similar materialsSerious eye damage/eye irritationNot classified based on available information.Not classified based on available information.Components:Ezetimibe:	Magn	esium stearate:			
Remarks : Based on data from similar materials Serious eye damage/eye irritation Not classified based on available information. Components: Ezetimibe: Species : Rabbit Result : No eye irritation Sinvastatin: Species : Rabbit Remarks : slight irritation Magnesium stearate: Species : Rabbit Remarks : slight irritation Magnesium stearate: Species : Rabbit Result : No eye irritation Magnesium stearate: Species Species : Based on data from similar materials Kasult : Based on data from similar materials May cause an allergic skin reaction.			:		
Serious eye damage/eye irritation Not classified based on available information. Components: Ezetimibe: Species : Rabbit Result : No eye irritation Sinvastatin: Species : Rabbit Remarks : slight irritation Magnesium stearate: Species : Rabbit Result : slight irritation Magnesium stearate: Species : Rabbit Result : No eye irritation Magnesium stearate: Species : Rabbit Result : No eye irritation Magnesium stearate: Species : Rabbit Result : No eye irritation Magnesium stearate: Species : Rabbit Result : Sno eye irritation Magnesium stearate: Species May cause an allergic skin reaction.					
Species : Rabbit Remarks : slight irritation Magnesium stearate: . . Species : Rabbit Result : No eye irritation Remarks : Based on data from similar materials Respiratory or skin sensitization . Skin sensitization May cause an allergic skin reaction. . .	<u>Comp</u> Ezetii Speci	oonents: mibe: es	ailable : :	Rabbit	on
Remarks : slight irritation Magnesium stearate: Species Species Result Result : No eye irritation Remarks : Based on data from similar materials Respiratory or skin sensitization Skin sensitization May cause an allergic skin reaction.	Simva	astatin:			
Magnesium stearate: Species : Rabbit Result : No eye irritation Remarks : Based on data from similar materials Respiratory or skin sensitization Skin sensitization May cause an allergic skin reaction.			:		
Species : Rabbit Result : No eye irritation Remarks : Based on data from similar materials Respiratory or skin sensitization Skin sensitization May cause an allergic skin reaction.	Rema	irks	:	slight irritation	
Result : No eye irritation Remarks : Based on data from similar materials Respiratory or skin sensitization Skin sensitization May cause an allergic skin reaction.	-				
Remarks : Based on data from similar materials Respiratory or skin sensitization Skin sensitization May cause an allergic skin reaction.			:		
Respiratory or skin sensitization Skin sensitization May cause an allergic skin reaction.			:		
Skin sensitization May cause an allergic skin reaction.	кеша	II K 5	•	Daseu on uata	
May cause an allergic skin reaction.	Resp	iratory or skin sensi	itizatio	'n	
	Skin	sensitization			
Respiratory sensitization	May c	ause an allergic skin	reaction	on.	
	Resp	iratory sensitization	l		

according to the OSHA Hazard Communication Standard



Version 7.1	Revision Date: 09/30/2023	SDS Number: 28137-00022	Date of last issue: 04/04/2023 Date of first issue: 11/04/2014
<u>Com</u>	oonents:		
Ezeti Test ⁻ Speci Resul	es	: Maximizatio : Guinea pig : negative	on Test
	astatin: ssment lt	: Probability : positive	or evidence of skin sensitization in humans
Test	es of exposure es od It	: negative	
Not cl	a cell mutagenicity lassified based on ava ponents:	ailable information.	
Cellu Geno	lose: toxicity in vitro	: Test Type: Result: neg	Bacterial reverse mutation assay (AMES) ative
Geno	toxicity in vivo	Result: neg : Test Type: cytogenetic Species: M	Mammalian erythrocyte micronucleus test (in vivo assay) ouse Route: Ingestion
	mibe: toxicity in vitro	: Test Type:	Bacterial reverse mutation assay (AMES) ctivation: with and without metabolic activation
			Chromosomal aberration n: Human lymphocytes ative
Geno	toxicity in vivo	Species: M Cell type: B	one marrow Route: Oral

according to the OSHA Hazard Communication Standard



rsion	Revision Date: 09/30/2023	SDS Number: 28137-00022	Date of last issue: 04/04/2023 Date of first issue: 11/04/2014			
Simu	astatin:					
	toxicity in vitro	: Test Type: Result: neg	Bacterial reverse mutation assay (AMES) pative			
		Test Type: Result: neg	Alkaline elution assay gative			
		Test Type: Result: neg	Chromosomal aberration gative			
		Test Type: Result: neg	In vitro mammalian cell gene mutation test gative			
Genot	toxicity in vivo	Species: M	Route: Oral			
	cell mutagenicity -		: Weight of evidence does not support classification as a germ cell mutagen.			
Magn	esium stearate:					
Genot	toxicity in vitro	Result: neg	In vitro mammalian cell gene mutation test gative Based on data from similar materials			
		Method: Ol Result: neg	Chromosome aberration test in vitro ECD Test Guideline 473 gative Based on data from similar materials			
		Result: neg	Bacterial reverse mutation assay (AMES) pative Based on data from similar materials			
Carci	nogenicity					
Not cl	assified based on ava	ailable information.				
<u>Comp</u>	oonents:					
Cellu		. D-4				
Speci Applic	es cation Route	: Rat : Ingestion				
	sure time	: 72 weeks : negative				
Ezetir	nibe:					
Speci		: Rat, female	9			
	cation Route sure time	: oral (feed) : 104 weeks				

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

ersion 1	Revision Date: 09/30/2023	SDS Number: 28137-00022	Date of last issue: 04/04/2023 Date of first issue: 11/04/2014
Result	t	: negative	
	ation Route ure time	: Rat, male : oral (feed) : 104 weeks : negative	
	ation Route ure time	: Mouse : oral (feed) : 104 weeks : negative	
Simva	astatin:		
Expos	ation Route ure time t Organs r Type	: Mouse : Oral : < 92 weeks : Harderian glan : Liver, Lungs : The significand	nd ce of these findings for humans is not certain.
	ation Route ure time ^r Type	: Rat : Oral : 2 Years : Liver, Thyroid : The significand	ce of these findings for humans is not certain.
IARC			ent at levels greater than or equal to 0.1% is r confirmed human carcinogen by IARC.
OSHA	•	nt of this product pre st of regulated carci	esent at levels greater than or equal to 0.1% is nogens.
NTP			ent at levels greater than or equal to 0.1% is ed carcinogen by NTP.
Not cla	ductive toxicity assified based on avail	able information.	
Cellul	onents:		
	s on fertility	: Test Type: On Species: Rat Application Ro Result: negativ	
Effects on fetal development		: Test Type: Fer Species: Rat Application Ro Result: negativ	

Ezetimibe:

according to the OSHA Hazard Communication Standard



Versio 7.1	n	Revision Date: 09/30/2023		S Number: 137-00022	Date of last issue: 04/04/2023 Date of first issue: 11/04/2014
Ef	ffects	on fertility	:	Test Type: Fertility/early embryonic development Species: Rat, male and female Fertility: NOAEL: > 1,000 mg/kg body weight Result: No effects on fertility., No fetotoxicity.	
Ef	Effects on fetal development		:	Test Type: Develo Species: Rat Application Route Developmental To Result: No advers	: Oral oxicity: NOAEL: > 1,000 mg/kg body weight
				Test Type: Develo Species: Rabbit Application Route Developmental To Result: No advers	: Oral oxicity: NOAEL: > 1,000 mg/kg body weight
Si	imvas	tatin:			
Ef	ffects	on fertility	:	Test Type: Fertility Species: Rat, mal Application Route Fertility: LOAEL: 2	e
E	ffects	on fetal development	:	Species: Rat Application Route Embryo-fetal toxic	o-fetal development : Oral ity.: NOAEL: 25 mg/kg body weight jenic effects., No adverse effects.
				Species: Rabbit Application Route Embryo-fetal toxic	o-fetal development : Oral ity.: NOAEL: 10 mg/kg body weight jenic effects., No adverse effects.
				Species: Rat Application Route Embryo-fetal toxic Result: Teratogen	ity.: LOAEL: 60 mg/kg body weight
М	lagnes	sium stearate:			
	-	on fertility	:	reproduction/dever Species: Rat Application Route Method: OECD Te Result: negative	
Ef	ffects	on fetal development	:	Test Type: Embry	o-fetal development

according to the OSHA Hazard Communication Standard



Version 7.1	Revision Date: 09/30/2023	SDS Number: 28137-00022	Date of last issue: 04/04/2023 Date of first issue: 11/04/2014
		Result: negati	oute: Ingestion ve ed on data from similar materials
	-single exposure		
	assified based on ava	ailable information.	
	-repeated exposure es damage to organs	(Liver, muscle, optic r	nerve, Eye) through prolonged or repeated expo-
Com	oonents:		
Simv	astatin:		
	et Organs ssment		optic nerve, Eye ge to organs through prolonged or repeated
Repe	ated dose toxicity		
Com	oonents:		
Cellu	lose:		
		: Rat : >= 9,000 mg/ł : Ingestion : 90 Days	(g
Ezeti	mibe:		
Speci NOAE Applic	es EL cation Route sure time	: Dog : 1,000 mg/kg : Oral : 90 d : No significant	adverse effects were reported
	EL cation Route sure time	: Rat : 1,500 mg/kg : Oral : 90 d : No significant	adverse effects were reported
	EL cation Route sure time	: Mouse : 500 mg/kg : Oral : 90 d : No significant	adverse effects were reported
	EL cation Route sure time	: Dog : 300 mg/kg : Oral : 1 y : No significant	adverse effects were reported

according to the OSHA Hazard Communication Standard



Version 7.1	Revision Date: 09/30/2023	SDS Number: 28137-00022	Date of last issue: 04/04/2023 Date of first issue: 11/04/2014	
Sir	nvastatin:			
	ecies	: Rat		
	DAEL	: 5 mg/kg		
	AEL plication Route	: 30 mg/kg : Oral		
	posure time	: 14 - 104 We	eks	
	rget Organs	: Liver, Testis	, Musculo-skeletal system, Eye	
•	ecies	: Dog		
-	AEL	: 10 mg/kg		
	plication Route	: Oral : 14 - 104 We	eks	
	rget Organs	: Liver, Testis		
	ecies	: Rabbit		
	DAEL	: 30 mg/kg		
-	AEL plication Route	: 50 mg/kg : Oral		
	rget Organs	: Liver, Kidne	у	
Ма	gnesium stearate:			
	ecies	: Rat		
-	DAEL	: > 100 mg/kg	l	
	plication Route	: Ingestion : 90 Days		
	marks		ata from similar materials	
As	piration toxicity			
No	t classified based on av	ailable information.		
<u>Co</u>	mponents:			
Ez	etimibe:			
No	t applicable			
Ex	perience with human	exposure		
Co	mponents:			
Ez	etimibe:			
Ing	jestion		Headache, Nausea, Vomiting, Diarrhea, flatu- le pain, upper respiratory tract infection, Back ain	
Sir	nvastatin:			
	in contact		ay produce an allergic reaction.	
ıng	jestion	dominal pair	ns: Liver upper respiratory tract infection, Headache, Ab n, constipation, Nausea ns: Musculo-skeletal system	1-

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

ersion Revision Date: 1 09/30/2023		SDS Number: 28137-00022		Date of last issue: 04/04/2023 Date of first issue: 11/04/2014	
ECTION	CTION 12. ECOLOGICAL INFORMATION				
Ecoto	oxicity				
<u>Comp</u>	oonents:				
Cellu	lose:				
Toxici	ty to fish	:	Exposure time: 48	pes (Japanese medaka)): > 100 mg/l 8 h on data from similar materials	
Ezetir	nibe:				
Toxici	ty to fish	:	Exposure time: 96 Method: OECD Te		
	ty to daphnia and other ic invertebrates	:	Exposure time: 48 Method: OECD Te		
Toxici plants	ty to algae/aquatic	:	0.317 mg/l Exposure time: 96 Method: OECD To		
			mg/l Exposure time: 96 Method: OECD Te		
Toxici icity)	ty to fish (Chronic tox-	:	NOEC (Pimephale Exposure time: 33 Method: OECD Te		
			Exposure time: 7	on variegatus (sheepshead minnow)): 4 mg d city at the limit of solubility.	
	ty to daphnia and other ic invertebrates (Chron- city)	:	Exposure time: 21	nagna (Water flea)): 0.282 mg/l d city at the limit of solubility.	
Toxici	ty to microorganisms	:	EC50: > 4.4 mg/l Exposure time: 3 Test Type: Respir Method: OECD To Remarks: No toxic	ation inhibition	
			NOEC: 4.4 ma/l	-	

NOEC: 4.4 mg/l

according to the OSHA Hazard Communication Standard



Versi 7.1	on	Revision Date: 09/30/2023		9S Number: 137-00022	Date of last issue: 04/04/2023 Date of first issue: 11/04/2014
				Exposure time: 3 Test Type: Respir Method: OECD Te Remarks: No toxic	ation inhibition
ę	Simvas	tatin:			
-	Toxicity to fish		:	LC50 (Pimephales Exposure time: 96 Method: OECD Te	
	Toxicity to daphnia and other aquatic invertebrates		:	EC50 (Daphnia m Exposure time: 48 Method: OECD Te	
	Toxicity to algae/aquatic plants		:	EC50 (Pseudokiro mg/l Exposure time: 96	chneriella subcapitata (green algae)): > 25 Sh
				NOEC (Pseudokir mg/l Exposure time: 96	chneriella subcapitata (green algae)): 25 Sh
-	Toxicity	to microorganisms	:	EC50: > 30 mg/l Exposure time: 3 Test Type: Respir Method: OECD Te	ation inhibition
				NOEC: 21 mg/l Exposure time: 3 Test Type: Respir Method: OECD Te	ation inhibition
	Magnes	sium stearate:			
	Toxicity		:	Exposure time: 48 Method: DIN 3841	
		to daphnia and other invertebrates	:	Exposure time: 47 Test substance: V Method: Directive	Vater Accommodated Fraction 67/548/EEC, Annex V, C.2. on data from similar materials
	Toxicity plants	to algae/aquatic	:	mg/l Exposure time: 72 Test substance: V Method: OECD Te	Vater Accommodated Fraction est Guideline 201 on data from similar materials

according to the OSHA Hazard Communication Standard



/ersion ′.1	Revision Date: 09/30/2023		DS Number: 137-00022	Date of last issue: 04/04/2023 Date of first issue: 11/04/2014
			mg/l Exposure time: 7 Test substance: Method: OECD 1	kirchneriella subcapitata (green algae)): > 1 2 h Water Accommodated Fraction Fest Guideline 201 on data from similar materials
Toxic	ity to microorganisms	:	Exposure time: 1 Test substance:	onas putida): > 100 mg/l 6 h Water Accommodated Fraction on data from similar materials
Persi	stence and degradabi	ility		
Com	oonents:			
Cellu Biode	lose: gradability	:	Result: Readily b	biodegradable.
	mibe: gradability	:	Result: Not readi Biodegradation: Exposure time: 2	
Stabil	ity in water	:	, ,	o(4.5 d) Fest Guideline 111
Simv	astatin:			
Biode	gradability	:	Result: rapidly de	egradable
Stabil	ity in water	:	Hydrolysis: 50 %	o(3.2 d)
-	esium stearate: gradability	:	Result: Not biode Remarks: Based	egradable on data from similar materials
Bioad	ccumulative potential			
Com	oonents:			
	mibe:			
Bioac	cumulation	:	Bioconcentration Exposure time: 9	is macrochirus (Bluegill sunfish) 1 factor (BCF): 173 97 d Fest Guideline 305
	ion coefficient: n- ol/water	:	log Pow: 4.36	
Simv	astatin:			

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

Version 7.1	Revision Date: 09/30/2023		DS Number: 137-00022	Date of last issue: 04/04/2023 Date of first issue: 11/04/2014
	ition coefficient: n- nol/water	:	log Pow: > 4.07	
Parti octai	Magnesium stearate: Partition coefficient: n- octanol/water Mobility in soil		log Pow: > 4	
<u>Com</u>	ponents:			
Ezet	imibe:			
	ibution among environ- tal compartments	:	log Koc: 4.35 Method: OECD	Fest Guideline 106
Othe	er adverse effects			
No d	lata available			
SECTION	N 13. DISPOSAL CONSI	IDEF	RATIONS	
Disp	oosal methods			
Was	te from residues	:		cordance with local regulations. f waste into sewer.
Cont	Contaminated packaging		Empty container	s should be taken to an approved waste recycling or disposal.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG		
UN number	:	UN 3077
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Simvastatin)
Class	:	9
Packing group	:	III
Labels	:	9
Environmentally hazardous	:	yes
IATA-DGR		
UN/ID No.	:	UN 3077
Proper shipping name	:	Environmentally hazardous substance, solid, n.o.s. (Ezetimibe, Simvastatin)
Class	:	9
Packing group	:	III
Labels	:	Miscellaneous
Packing instruction (cargo aircraft)	:	956
Packing instruction (passen- ger aircraft)	:	956
Environmentally hazardous	:	yes

If not otherwise specified: Dispose of as unused product.

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

Version 7.1	Revision Date: 09/30/2023	SDS Number: 28137-00022	Date of last issue: 04/04/2023 Date of first issue: 11/04/2014
IMDG-Code UN number Proper shipping name		: UN 3077 : ENVIRONME N.O.S. (Ezetimibe, S	ENTALLY HAZARDOUS SUBSTANCE, SOLID,
Class Packing group Labels EmS Code Marine pollutant		: 9 : III : 9 : F-A, S-F : yes	
Transport in bulk accordir Not applicable for product as		-	ARPOL 73/78 and the IBC Code
Dom	estic regulation		
Prop Class Pack Labe ERG	D/NA number er shipping name s ing group ls Code ne pollutant	(Ezetimibe, 3 9 III CLASS 9 171 yes(Ezetimib	ally hazardous substance, solid, n.o.s. Simvastatin) e, Simvastatin) s only to containers over 119 gallons or 450

Shipment by ground under DOT is non-regulated; however it may be shipped per the applicable hazard classification to facilitate multi-modal transport involving ICAO (IATA) or IMO.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards	:	Combustible dust Respiratory or skin sensitization Specific target organ toxicity (single or repeated exposure) Skin corrosion or irritation
		Skin conosion of initiation

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

Version 7.1	Revision Date: 09/30/2023	SDS Number: 28137-00022	Date of last issue: 04/04/2023 Date of first issue: 11/04/2014			
SARA	SARA 313		This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.			
US St	tate Regulations					
Penn	sylvania Right To Kn	ow				
	D-Glucose, 4-O-β Cellulose Ezetimibe Simvastatin Croscarmellose s	с	syl-, monohydrate 64044-51-5 9004-34-6 163222-33-1 79902-63-9 74811-65-7			
	ornia Prop. 65	n ovnogo vou to ak	homicals including fort Putul 4 methowshand			
which			hemicals including tert-Butyl-4-methoxyphenol, o cause cancer. For more information go to			
Califo	ornia Permissible Exp	osure Limits for	Chemical Contaminants			
	Cellulose Magnesium stear	ate	9004-34-6 557-04-0			
The i	ngredients of this pro	oduct are reporte	d in the following inventories:			
AICS		: not determi	ined			
DSL		: not determi	ined			
IECS	C	: not determi	ined			


SECTION 16. OTHER INFORMATION

Further information

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation



OSHA Z-1 / TWA OSHA Z-3 / TWA OSHA Z-3 / TWA COSHA Z-3 / TWA

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Pre-

according to the OSHA Hazard Communication Standard



Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
7.1	09/30/2023	28137-00022	Date of first issue: 11/04/2014

vention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-
Data Sheet		cy, http://echa.europa.eu/

09/30/2023

Revision Date :

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8